The Journal of urology
-
The Journal of urology · May 2013
Randomized Controlled TrialTranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study.
Bleeding is a significant morbidity associated with percutaneous nephrolithotomy. This study was conducted to evaluate the safety and efficacy of the antifibrinolytic agent tranexamic acid in reducing blood loss in patients undergoing percutaneous nephrolithotomy. ⋯ The use of tranexamic acid in percutaneous nephrolithotomy is safe, and is associated with reduced blood loss and a lower complication rate.